AbbVie Inc (ABBV)vsHarmony Biosciences Holdings (HRMY)
ABBV
AbbVie Inc
$257.60
-2.16%
HEALTHCARE · Cap: $447.53B
HRMY
Harmony Biosciences Holdings
$35.86
0.00%
HEALTHCARE · Cap: $1.94B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 6887% more annual revenue ($62.82B vs $899.11M). HRMY leads profitability with a 16.2% profit margin vs 5.8%. HRMY trades at a lower P/E of 13.6x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
HRMY
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-78.8%
Fair Value
$147.26
Current Price
$257.60
$110.34 premium
Intrinsic value data unavailable for HRMY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Reasonable price relative to book value
16.6% revenue growth
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Earnings declined 29.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.42 suggests the stock is reasonably priced for its growth.
Bull Case : HRMY
The strongest argument for HRMY centers on Altman Z-Score, Debt/Equity, P/E Ratio. Profitability is solid with margins at 16.2% and operating margin at 17.3%. Revenue growth of 16.6% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 124.8x leaves little room for execution misses.
Bear Case : HRMY
The primary concerns for HRMY are Market Cap, Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while HRMY is a growth play — different risk/reward profiles.
HRMY carries more volatility with a beta of 0.94 — expect wider price swings.
HRMY is growing revenue faster at 16.6% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 53/100) and 12.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Harmony Biosciences Holdings
HEALTHCARE · BIOTECHNOLOGY · USA
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?